Hem n Onc 8-5 (1) Flashcards
After being diagnosed with lung cancer, this patient presents with purple streaks on the abdomen, moon face, facial hair above the upper lip, and fatty tissue deposits between the shoulder, among other symptoms. Weight gain and redistribution of body fat (in contrast to the cachexia typical of cancers alone), buffalo hump (fatty tissue deposits between the shoulders) and moon facies are classic signs of?
Cushing syndrome
The patient’s Cushing syndrome is a paraneoplastic syndrome due to underlying small cell lung carcinoma (SCLC). SCLC is notorious for production of adrenocorticotropic hormone (ACTH) and antidiuretic hormone (ADH). Excessive ACTH production leads to excessive glucocorticoids, and can result in?
Cushing syndrome. Poor wound healing (due to inhibition of collagen synthesis by glucocorticoids) and facial plethora are also part of Cushing syndrome.
The increased glucocorticoid activity in Cushing syndrome would more likely cause decreased, not increased, bone density. Cold intolerance and constipation are symptoms of hypothyroidism, whereas proximal muscle weakness, diarrhea and palpitations are symptoms of ?
hyperthyroidism. Nipple discharge would be explained by a diagnosis of prolactinoma, a benign tumor of the pituitary gland.
The patient has breast cancer, which is the second leading cause of cancer-related mortality among women, after lung cancer. Whereas primary disease prevention measures aim to prevent the onset of specific diseases, secondary disease prevention measures promote ?
Early detection and treatment of a disease
Among the choices offered, annual mammography is the best secondary prevention measure and has been shown to reduce breast cancer mortality rates by promoting early detection. In this case, the disease has already been detected by biopsy; so annual mammography would prevent the recurrence of local or metastatic disease.
Monthly breast self-examination, annual breast ultrasound, and annual screening X-ray of the chest also serve as?
secondary disease prevention measures. However, none of those methods has been shown to reduce breast cancer mortality rates. Prophylactic bilateral mastectomy in high-risk patients and smoking cessation help reduce the risk of breast cancer onset. Thus, they serve as primary disease prevention measures.
Thalassemia is an inherited mutation in one or more of the genes involved in hemoglobin production. Hemoglobin is transported throughout the body by RBCs. So in effect, this question is asking, what organ is responsible for RBC production in a 7-month-old infant?
in utero, RBC production (called erythropoiesis) begins in the yolk sac at week 3 and continues until week 8. The liver takes over erythropoiesis from weeks 6 until birth, with help from the spleen during weeks 10 to 28.
Starting at 18 weeks’ gestation ?
The bone marrow steps up and begins to take over this crucial job. Up to about age 20 years, erythropoiesis occurs mainly in the marrow of the long bones such as the femur and tibia. After that, most erythropoiesis occurs in the pelvis, vertebrae, sternum, and ribs.
Bone marrow remains the site of erythropoiesis throughout life, including the 7-month-old infant in this question.
Thalassemia is the result of abnormal hemoglobin production. The liver is not involved in the production of hemoglobin in a 7-month-old infant.
Thalassemia is the result of abnormal hemoglobin production. The lungs help get oxygen into the bloodstream, but are not involved in the production of hemoglobin in a 7-month-old infant.
Thalassemia is the result of ?
abnormal hemoglobin production. The spleen is not involved in the production of hemoglobin in a 7-month-old infant.
The yolk sac protects and feeds an embryo through the first trimester of pregnancy. After that, the yolk sac shrinks and disappears. It would not be involved in the pathophysiology of this 7-month-old’s disorder.
This patient is a BRCA1 carrier treated for breast cancer with chemotherapy. The low values of her initial CBC strongly suggest that this patient was experiencing myelosuppression from her chemotherapeutic treatment.
The patient’s improved CBC values after she was placed on leucovorin indicate that her chemotherapy was most likely?
Methotrexate. Methotrexate is a chemotherapeutic agent associated with myelosuppression. It is an S phase-specific antimetabolite that acts as a folic acid analog and reversibly inhibits dihydrofolate reductase, interfering with nucleotide synthesis.
Common adverse effects of methotrexate include diarrhea, nausea and vomiting, alopecia, damage to the liver and kidney, and myelosuppression that is reversible with leucovorin (folinic acid). Leucovorin bypasses the block created by methotrexate by supplying folinic acid, the necessary factor for DNA synthesis, and allowing for bone marrow repletion.
5-Fluorouracil inhibits thymidylate synthesis; cyclophosphamide acts by cross-linking DNA; doxorubicin is an intercalating agent; and paclitaxel stabilizes?
microtubules. Tamoxifen, a selective estrogen receptor modulator, is not associated with myelosuppression.
Methotrexate is a folic acid analog that inhibits dihydrofolate reductase and causes myelosuppression. This complication can be reversed with?
leucovorin rescue therapy, which supplies folinic acid. Other common adverse effects of methotrexate are diarrhea, vomiting, and liver and kidney damage.
This patient is presenting with recurrent severe knee pain with restriction of motion and ecchymoses. The hematocrit, leukocytes, thrombocytes, bleeding time, and international normalized ratio values are all within normal limits, making infection and platelet deficiency less likely. The combination of recurrent ecchymosis and knee pain in a male child with absence of trauma, platelet deficiency, or infection places hemophilia high on the differential. Hemarthrosis of weight-bearing joints, as seen in this patient, is a common complication of?
hemophilia A, because these and other joints are principal sites of bleeding. Partial thromboplastin time would be elevated. In a patient with hemophilia A, the factor VIII assay would reveal a deficiency.
Factor VIII deficiency (hemophilia A) is inherited as an X-linked recessive disorder. Up to 30% of cases result from a de novo mutation. A deficiency of factor VIII results in?
Easy bruising and hemarthrosis. The severity of symptoms depends on the percentage of activity of factor VIII. Mild is greater than 5% but less than 40%, moderate is between 1% and 5%, and severe is less than 1%. The disease can be treated with factor replacement and/or desmopressin.
Extensive trauma from any etiology would result in an inflammatory reaction of the knee, and erythema and warmth would be observed on physical examiantion.
Inflammatory signs would also be found in septic arthritis caused by Staphylococcus aureus colonization, including fever, pain, leukocytosis, impaired range of motion, and warmth and erythema over the joint.
Coagulopathies from immune destruction of platelets or a decrease in?
von Willebrand factor may result in microhemorrhages of the mucous membranes (nasal passages, gums) and skin. However, it is very unlikely that hemarthrosis would occur.
The patient presents with constitutional B symptoms (fever, night sweats, and weight loss), and he is going to be treated with a bone marrow transplant; these facts strongly support a diagnosis of Hodgkin lymphoma. Chemotherapy is often effective in treating the disease, but high-dose chemotherapy can destroy the bone marrow. One way to manage this adverse effect is for the patient to undergo?
Autologous grafting by having his stem cells harvested (remember, Hodgkin lymphoma is not a neoplasm of stem cells), undergoing chemotherapy, then replacing the harvested stem cells back into the patient to help replenish the bone marrow.
An autogeneic graft, also known as an autologous or self-graft, involves transplantation of the patient’s own tissue from one site to another. These grafts are commonly used for skin grafts, coronary artery bypass surgery (vein), and bone or cartilage transplants. There is no need for immunosuppression after autogenic grafts.
An autogeneic graft, also known as an autologous or self-graft, involves transplantation of the patient’s own tissue from one site to another. These grafts are commonly used for?
skin grafts, coronary artery bypass surgery (vein), and bone or cartilage transplants. There is no need for immunosuppression after autogenic grafts.